ONBI One Bio Corp (CE)

ONE Bio, Corp. ("ONE" or the "Company") (OTCBB: ONBI), an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural and health supplements and organic products, announces unaudited results for the third quarter and year-to-date (YTD) ended September 30, 2010. Summary of financial results include the following:

Revenue for the three months ended September 30, 2010 reached $13,504,890, compared to $4,157,806 for the three months ended September 30, 2009 (an increase of 225%), bringing revenue for the nine months ended September 30, 2010 to $37,347,194 compared to $8,625,175 for the same period last year (an increase of 333%).

Net income for the three months ended September 30, 2010 reached $1,912,286, compared to $849,970 for the three months ended September 30, 2009 (an increase of 125%), bringing net income for the nine months ended September 30, 2010, to $5,898,845 compared to $2,072,065 for the same period last year (an increase of 185%).

The increase in revenue and net income in the third quarter of 2010 is primarily attributable to the acquisitions the Company completed during the third quarter of 2009 and the increase in demand for the Company's chemical and herbal extracts and organic products.

Earnings per share for the three months ended September 30, 2010 reached $0.31 ($0.29 on a fully diluted basis), compared to $0.18 ($0.17 on a fully diluted basis) for the three months ended September 30, 2009 bringing earnings per share for the nine months ended September 30, 2010 to $0.98 ($0.93 on a fully diluted basis) compared to $0.44 ($0.43 on a fully diluted basis) for the same period last year.

               Three Months ended         Nine Months ended
                  September 30,             September 30,
            ------------------------  ------------------------
                2010         2009         2010         2009
Revenues    $13,504,890  $ 4,157,806  $37,347,194  $ 8,625,175
Cost of
 sales        8,484,199    2,068,381   23,287,108    3,909,654
            -----------  -----------  -----------  -----------
Gross
 profits      5,020,691    2,089,425   14,060,086    4,715,521
            -----------  -----------  -----------  -----------
Operating
 expenses
  G&A
   expenses   1,436,565      428,220    3,695,867      923,031
  R&D
   expenses      73,248      126,625      186,856      199,664
  Selling &
   marketing
   expenses     380,775       43,543      590,898      120,100
              1,890,588      598,388    4,473,621    1,242,795
            -----------  -----------  -----------  -----------
Income from
 operations   3,130,103    1,491,037    9,586,465    3,472,726
Interest and
 financing
 expense       (172,689)     (53,575)    (546,979)     (53,575)
Interest
 income           9,316        1,693       21,935        3,365
Other
 income/
 (expense)     (231,871)      10,105     (592,503)       1,699
            -----------  -----------  -----------  -----------
Income
 before
 income
 taxes        2,734,859    1,449,260    8,468,918    3,424,215
Provision
 for income
 taxes         (710,510)    (396,033)  (2,214,710)    (912,406)
            -----------  -----------  -----------  -----------
Net income    2,024,349    1,053,227    6,254,208    2,511,809
  non-
   controlling
   interest    (112,063)    (203,257)    (355,363)    (439,744)
            -----------  -----------  -----------  -----------
Net income
 attributable
 to Company $ 1,912,286  $   849,970  $ 5,898,845  $ 2,072,065
            ===========  ===========  ===========  ===========
Earnings per
 share
  - Basic   $      0.31  $      0.18  $      0.98  $      0.44
            ===========  ===========  ===========  ===========
  - Diluted $      0.29  $      0.17  $      0.93  $      0.43
            ===========  ===========  ===========  ===========

"Third quarter results have met our expectations. Asia's robust economic growth continues to fuel demand for our products," stated Marius Silvasan, ONE's CEO. "The third quarter is typically our second strongest quarter with fourth quarter being our strongest. We foresee continued improvements in our operating results in the fourth quarter," added Silvasan.

About ONE Bio, Corp. ONE Bio, Corp. ("ONE") (OTCBB: ONBI) (www.onehcorp.com) headquartered in Miami, FL, is an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural supplements and organic products. ONE is focused on capitalizing on the rapidly growing markets of the Asia Pacific region. Key products include widely recognized Solanesol, CoQ10, Resveratrol and 5-HTP, organic fertilizers, and organic bamboo health food and beverages. ONE's growth plan targets an aggressive acquisition driven strategy supported by strong organic growth. Through ONE, small private companies gain access to capital, experienced management and strategic insight. ONE builds strong synergies amongst all subsidiaries to enhance shareholder value. ONE is working with each subsidiary to promote organic and acquisition driven growth.

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). ONE Bio, Corp. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," or "anticipates," and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful integration of diversified growth companies, impact of the company's expansion plan, and new business development success, future financial results, development and acquisition of new product lines and services, the impact of competitive products or pricing from technological changes, the effect of economic conditions and other uncertainties. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the expectations contained in any such forward-looking statements. These risks include, but are not limited to: failure to manage operating expenses or integrate new companies and/or technologies, each of which could have a material impact on our business, our financial results, and the company's stock price. These risks and other factors are detailed in the Company's regular filings with the U.S. Securities and Exchange Commission. Most of these factors are difficult to predict accurately and are generally beyond the Company's control. Forward-looking statements speak only as to the date they are made and ONE Bio, Corp. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Company Contact: Jeanne Chan Senior VP Tel. +888-676-4445 jchan@onehcorp.com Contact: Investor Relations & Corporate Communications 888-676-4445 ir@onehcorp.com